This trial is testing whether dapagliflozin can improve the clinical outcome for people who have been hospitalized for acute heart failure, compared to placebo.
- Acute Heart Failure
- Heart Failure
1 Primary · 6 Secondary · Reporting Duration: 2 months
Side Effects for
2 Treatment Groups
1 of 2
1 of 2
2400 Total Participants · 2 Treatment Groups
Primary Treatment: Dapagliflozin · Has Placebo Group · Phase 4
Who is running the clinical trial?
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is this experiment the initial implementation of its kind?
"At present, there are 63 active trials for Dapagliflozin being conducted in 235 cities and 50 countries. This drug was initially trialled by AstraZeneca back in 2014; the study involved 700 individuals and successfully completed its initial drug approval stage. Since then, a total of 18457 clinical trial have been concluded." - Anonymous Online Contributor
Is this trial currently recruiting participants?
"This study, which had its inception on September 24th of 2020, is still actively recruiting participants per the information available on clinicaltrials.gov. Its most recent edit was made on December 9th 2021." - Anonymous Online Contributor
What conditions are generally treated by administering Dapagliflozin?
"Dapagliflozin is widely prescribed for pharmaceutical preparations, as well as multiple other medical conditions including diet-related illnesses, exercise-induced health issues, and an insufficient response to monotherapy." - Anonymous Online Contributor
How many participants are being treated as part of this trial?
"Affirmative. According to the information displayed on clinicaltrials.gov, this trial was first published in September of 2020 and has since been revised as recently as December 2021. Currently 2400 participants have signed up and are enrolled at one site." - Anonymous Online Contributor
How does Dapagliflozin impact patient safety?
"There is ample evidence confirming dapagliflozin's safety, so it scored a 3." - Anonymous Online Contributor